772 related articles for article (PubMed ID: 23811113)
1. Liposomal-praziquantel: efficacy against Schistosoma mansoni in a preclinical assay.
Frezza TF; Gremião MP; Zanotti-Magalhães EM; Magalhães LA; de Souza AL; Allegretti SM
Acta Trop; 2013 Oct; 128(1):70-5. PubMed ID: 23811113
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of hyperbaric oxygen for experimental treatment of schistosomiasis mansoni using praziquantel-free and encapsulated into liposomes: assay in adult worms and oviposition.
Frezza TF; de Souza AL; Prado CC; de Oliveira CN; Gremião MP; Giorgio S; Dolder MA; Joazeiro PP; Allegretti SM
Acta Trop; 2015 Oct; 150():182-9. PubMed ID: 26215128
[TBL] [Abstract][Full Text] [Related]
3. Adult worm tegumental damage and egg-granulomas in praziquantel-resistant and -susceptible Schistosoma mansoni treated in vivo.
Liang YS; Coles GC; Dai JR; Zhu YC; Doenhoff MJ
J Helminthol; 2002 Dec; 76(4):327-33. PubMed ID: 12498638
[TBL] [Abstract][Full Text] [Related]
4. Parasitological, hematological and ultrastructural study of the effect of COX-2 inhibitor, pyocyanin pigment and praziquantel, on S. mansoni infected mice.
Mohamed AH; Ezz El-Din N; Fahmy ZH; El-Shennawy AM; Hassan E
J Egypt Soc Parasitol; 2006 Apr; 36(1):197-220. PubMed ID: 16605111
[TBL] [Abstract][Full Text] [Related]
5. Anthelmintic activity in vitro and in vivo of Baccharis trimera (Less) DC against immature and adult worms of Schistosoma mansoni.
de Oliveira RN; Rehder VL; Oliveira AS; Jeraldo Vde L; Linhares AX; Allegretti SM
Exp Parasitol; 2014 Apr; 139():63-72. PubMed ID: 24602876
[TBL] [Abstract][Full Text] [Related]
6. Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection.
El-Feky GS; Mohamed WS; Nasr HE; El-Lakkany NM; Seif El-Din SH; Botros SS
Antimicrob Agents Chemother; 2015; 59(6):3501-8. PubMed ID: 25845870
[TBL] [Abstract][Full Text] [Related]
7. Schistosoma mansoni eggs as a target for praziquantel: efficacy of oral application in mice.
Giboda M; Smith JM
J Trop Med Hyg; 1994 Apr; 97(2):98-102. PubMed ID: 8170010
[TBL] [Abstract][Full Text] [Related]
8. Parasitological and histo-pathological studies on schistosomiasis mansoni infected mice and treated with praziquatel and/or oltipraz.
Morsy GH
J Egypt Soc Parasitol; 2009 Aug; 39(2):687-701. PubMed ID: 19795775
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a method for induction of praziquantel resistance in Schistosoma mansoni.
Lotfy WM; Hishmat MG; El Nashar AS; Abu El Einin HM
Pharm Biol; 2015 Aug; 53(8):1214-9. PubMed ID: 25609146
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of prophylactic efficacy and safety of praziquantel-miltefosine nanocombination in experimental Schistosomiasis mansoni.
Eissa MM; El-Azzouni MZ; El-Khordagui LK; Abdel Bary A; El-Moslemany RM; Abdel Salam SA
Acta Trop; 2020 Dec; 212():105714. PubMed ID: 32950482
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of subcurative dose praziquantel on Schistosoma mansoni infected mice and resistance to challenge infection after treatment.
Chaiworaporn R; Maneerat Y; Rojekittikhun W; Ramasoota P; Janecharut T; Matsuda H; Kitikoon V
Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):846-52. PubMed ID: 16295535
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta, Egypt.
Barakat R; El Morshedy H
Parasitology; 2011 Apr; 138(4):440-6. PubMed ID: 21078223
[TBL] [Abstract][Full Text] [Related]
13. Praziquantel efficacy in mice infected with PZQ non-susceptible S. mansoni isolate treated with artemether: parasitological, biochemical and immunohistochemical assessment.
Botros SS; Hammam O; Mahmoud M; Bergquist R
APMIS; 2010 Sep; 118(9):692-702. PubMed ID: 20718722
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the potential therapeutic effects of omeprazole in Schistosoma mansoni infected mice.
Ellakany AR; Elgendy DI; Alshenawy HA; Abdel Ghaffar AE
Parasitol Res; 2019 Dec; 118(12):3399-3408. PubMed ID: 31655904
[TBL] [Abstract][Full Text] [Related]
15. Response of Schistosoma mansoni isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure.
Sabra AN; Botros SS
J Parasitol; 2008 Apr; 94(2):537-41. PubMed ID: 18564758
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger.
Garba A; Lamine MS; Barkiré N; Djibo A; Sofo B; Gouvras AN; Labbo R; Sebangou H; Webster JP; Fenwick A; Utzinger J
Acta Trop; 2013 Nov; 128(2):334-44. PubMed ID: 22940014
[TBL] [Abstract][Full Text] [Related]
17. Niosomes for enhanced activity of praziquantel against Schistosoma mansoni: in vivo and in vitro evaluation.
Zoghroban HS; El-Kowrany SI; Aboul Asaad IA; El Maghraby GM; El-Nouby KA; Abd Elazeem MA
Parasitol Res; 2019 Jan; 118(1):219-234. PubMed ID: 30421348
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of a Brazilian wild rodent isolate of Schistosoma mansoni to praziquantel in mice.
Costa-Silva M; Barros Lde A; Garcia JS; Neves RH; Rodrigues-Silva R; Machado-Silva JR; Maldonado-Júnior A
Exp Parasitol; 2012 Apr; 130(4):394-9. PubMed ID: 22343042
[TBL] [Abstract][Full Text] [Related]
19. Potential antifibrotic effects of AT1 receptor antagonist, losartan, and/or praziquantel on acute and chronic experimental liver fibrosis induced by Schistosoma mansoni.
El-Lakkany NM; El-Maadawy W; Ain-Shoka A; Badawy A; Hammam O; Ebeid F
Clin Exp Pharmacol Physiol; 2011 Oct; 38(10):695-704. PubMed ID: 21762203
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and bioavailability of different praziquantel brands.
Botros S; El-Lakkany N; Seif el-Din SH; Sabra AN; Ibrahim M
Exp Parasitol; 2011 Feb; 127(2):515-21. PubMed ID: 21044626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
